FDA Describes CBD as Beneficial for Neurological Disorders
The United Nations (U.N.) has asked the Food and Drug Administration (FDA) to gather responses from the public regarding cannabidiol (CBD). This request by the FDA to collect comments concerning the possible re-classification of CBD proves that as time progresses, cannabis is one step closer to being recognized as a medically beneficial substance. CBD stands among 16 other substances under review by the U.N. and the FDA.
The U.N.’s World Health Organization stated that it will “consider whether to recommend that certain international restrictions be placed on these drugs.” Cannabis currently exists as a Schedule I drug under the Controlled Substances Act. Currently, the FDA website states that the administration, “has not found [cannabis] to be safe or effective for the treatment of any disease or condition. Study of marijuana in clinical trial settings is needed to assess the safety and effectiveness of marijuana for medical use.” However, given their recent request for public comments about cannabis, the FDA has revealed that their stance on cannabis may soon evolve into declaring the substance as medically beneficial. In the official notice released last week by Deputy Commissioner of Policy, Anna K. Abram, CBD was stated to have, “shown to be beneficial in experimental models of several neurological disorders.”
The Deputy Commissioner for Policy also wrote the FDA will consider the public comments as it prepares a “response from the United States to the World Health Organization regarding the abuse liability and diversion” of the 17 substances under consideration. Comments may be sent in electronically or in written format and must be received by September 13, 2017. Those who have had positive experiences in regards to CBD are encouraged to share their stories. To receive further detail and instruction on response submission, visit the federal website regulations.gov.
